• Proceedings of the Korean Society of Veterinary Pathology Conference
• /
• 2005.11a
• /
• pp.53-54
• /
• 2005

• Korean Journal of Veterinary Service
• /
• v.30 no.4
• /
• pp.533-538
• /
• 2007

A 16-year-old female mixed dog was submitted for examination at the pathology division of national veterinary research and quarantine service (NVRQS). Grossly, white or grayish spherical, multinodular, firm to friable masses were present in the tibiofibula to the pharenge area of the right limb, and dysphagia, breathing difficulties and tachypnea were shown. Various-sized white or grayish black masses were scattered in lungs and diaphragm and one mass was observed in the trachea and in the jejunum, respectively. Histopathologically, the neoplastic cells were composed of polygonal or spindle shaped cells with various sized round to oval nuclei and abundant cytoplasm. These cells formed lobules or nests separated by fine connective tissue and contained little amount of melanin pigments. Melanin pigments were stained dark gray or black with Fontana-Masson method. Melanosomes were also ultrastructurally demonstrable by electron microscopy. Based on above results, the present case was diagnosed as canine malignant melanoma originating from the lower limb and digit.

• Journal of Veterinary Science
• /
• v.25 no.1
• /
• pp.15.1-15.15
• /
• 2024

Background: The anti-programmed death 1 (PD-1) antibody has led to durable clinical responses in a wide variety of human tumors. We have previously developed the caninized anti-canine PD-1 antibody (ca-4F12-E6) and evaluated its therapeutic properties in dogs with advance-staged oral malignant melanoma (OMM), however, their therapeutic effects on other types of canine tumors remain unclear. Objective: The present clinical study was carried out to evaluate the safety profile and clinical efficacy of ca-4F12-E6 in dogs with advanced solid tumors except for OMM. Methods: Thirty-eight dogs with non-OMM solid tumors were enrolled prospectively and treated with ca-4F12-E6 at 3 mg/kg every 2 weeks of each 10-week treatment cycle. Adverse events (AEs) and treatment efficacy were graded based on the criteria established by the Veterinary Cooperative Oncology Group. Results: One dog was withdrawn, and thirty-seven dogs were evaluated for the safety and efficacy of ca-4F12-E6. Treatment-related AEs of any grade occurred in 13 out of 37 cases (35.1%). Two dogs with sterile nodular panniculitis and one with myasthenia gravis and hypothyroidism were suspected of immune-related AEs. In 30 out of 37 dogs that had target tumor lesions, the overall response and clinical benefit rates were 6.9% and 27.6%, respectively. The median progression-free survival and overall survival time were 70 days and 215 days, respectively. Conclusions: The present study demonstrated that ca-4F12-E6 was well-tolerated in non-OMM dogs, with a small number of cases showing objective responses. This provides evidence supporting large-scale clinical trials of anti-PD-1 antibody therapy in dogs.

• Journal of Veterinary Clinics
• /
• v.26 no.1
• /
• pp.36-40
• /
• 2009

The purpose of this study was to determine the incidence and therapeutic outcomes of canine oral tumors in Korea. Medical records of dogs presented with oral tumor at the Veterinary Medical Teaching Hospital of Seoul National University from 2002 to 2007 were reviewed. The predominant breeds were Yorkshire terrier (n=14), miniature poodle (n=7), Shih Tzu (n=6), and maltese (n=4), in order. The mean age at onset was $10.0{\pm}3.8$ years. The most common tumor types included fibrous epulis (n=13), malignant melanoma (n=12), acanthomatous epulis (n=4), and squamous cell carcinoma (n=3). Surgical removal was performed in 29 cases; simple excision in 18 cases, partial mandibulectomy in 8 cases, and partial maxillectomy in 3 dogs. Outcomes of surgery were various according to the tumor types. Prognosis of dogs with fibrous epulis and acanthomatous epulis was good and that of dogs with malignant melanoma was poor.